^
Association details:
| Biomarker: | CD8 positive |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | AiRuiKa (camrelizumab) (PD1 inhibitor) + famitinib (SHR 1020) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial
Published date:
03/25/2022
Excerpt:
We conducted the phase II FUTURE-C-Plus trial to assess the feasibility of combining famitinib (an angiogenesis inhibitor), camrelizumab (a PD-1 monoclonal antibody) and chemotherapy in advanced immunomodulatory TNBC patients...Within 48 enrolled patients, the objective response rate was 81.3% (95% CI, 70.2-92.3), and the median progression-free survival was 13.6 months (95% CI, 8.4-18.8)...Patients with CD8 and/or PD-L1- positive tumors benefit more from this regimen. PKD1 somatic mutation indicates worse progression-free and overall survival.
Secondary therapy:
albumin-bound paclitaxel
DOI:
10.1186/s12943-022-01536-6
Trial ID:
Source:
Title:
Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study.
Published date:
05/19/2021
Excerpt:
IM subtype was defined as CD8+...48 patients were enrolled. Confirmed objective responses were achieved in 39 (81.3%; 95% CI 70.2%-92.3%) of 48 patients...Addition of famitinib to camrelizumab and nab-paclitaxel showed promising antitumour activity as first-line therapy...
Secondary therapy:
albumin-bound paclitaxel
DOI:
10.1200/JCO.2021.39.15_suppl.1007
Trial ID:
